ogochukwu osita izu

Haematologist, researcher. a curious guy

[ogochukwu osita izu @docIzuog1995]

https://t.co/tJJfxd3mb3
All patients, MYD88 mutant or not, had CD5, CD23,CD19 expression, and the vast majority 96.6% showed CD200 positivity..... only 38.8% of MYD88MUT cases had a classic “score 5” immunophenotype by the Matutes scoring system, compared to 67.2% of MYD88WT

[ogochukwu osita izu @docIzuog1995]

@drkeithsiau Carcinoma of the ampulla of Vater

[ogochukwu osita izu @docIzuog1995]

https://t.co/CBClInuAFE
Vibecotamab was active in low-blast myeloid diseases, although the durability of responses was modest.

[ogochukwu osita izu @docIzuog1995]

"We suspect that the disparity we see in AA and in studies West Africa, may or may not be present in East Africa. Which is why we are studying the Somali population in Minnesota currently".
https://t.co/nfBetlYZc6
I want to study the Western African population @VincentRK

[ogochukwu osita izu @docIzuog1995]

I know that Bexobrutideg is in phase 2 clinical trial; DAYBreak (NCT07221500). But will degrading BTK rewrite the rules of resistance, or simply redraw its boundaries? 🤔
That..... I don't know 😐 @DrHKantarjian @lymphomahub
https://t.co/RY9OIbUU1z

[ogochukwu osita izu @docIzuog1995]

@g_diets_ I believe it should be cutting refined and high glycemic index carbs and not carbs entirely as they are the cheapest source of ATP. Also I don't think a GFR <90ml/min is already dangerous. Many normal adults have it. But dietary modification should be emphasized.

[ogochukwu osita izu @docIzuog1995]

@HenrychihangFu1 I think it's too early to call..... But I agree, it will become more selective in the future.....

[ogochukwu osita izu @docIzuog1995]

MajesTEC-5!

[ogochukwu osita izu @docIzuog1995]

Across arms, the MRD-negative CR rate was 91.8% by the premaintenance timepoint; the MRD negativity rate was 100% in evaluable samples at postinduction cycle 3 (1 × 10−5, cycle 6 (1 × 10−5 and 1 × 10−6 and premaintenance (1 × 10−5); the ORR was 100%
https://t.co/kangtPn8Gc

[ogochukwu osita izu @docIzuog1995]

@docakx Sickle cell disease ......
https://t.co/jAgM1LuDcb

[ogochukwu osita izu @docIzuog1995]

Similar to earlier studies, early exposure to chemotherapy seems to play a role in the incidence of a second cancer...... Should exposure to chemo be limited to prevent such reoccurrence? 🤔
@Papa_Heme @HenrychihangFu1
https://t.co/9Th8UW4RNk

[ogochukwu osita izu @docIzuog1995]

https://t.co/WX5jMlhWAI

Accelerated 5-day, inpatient, venetoclax ramp-up is feasible, with a 2.5% rate of laboratory tumor lysis syndrome (TLS) and no clinical TLS.

[ogochukwu osita izu @docIzuog1995]

https://t.co/cD1QnM3Vi5

[ogochukwu osita izu @docIzuog1995]

Meanwhile.....
The SPEARHEAD-1 phase trial for advanced synovial sarcoma showed

• ORR: 43%
• CR: 3.6%
• Median DoR: 5.3 months
CRS and pleural effusion were the most common serious AEs reported in at least 5% of patients.
https://t.co/shmxUZbArf

[ogochukwu osita izu @docIzuog1995]

The injection, also known as satri-cel, is ⁠globally the first approved CAR-T cell therapy for solid tumors.
The median follow-up time for PFS was 9·07 months (95% CI 6·21–13·01) in the satri-cel grp and 3·45 months (2·89–not estimable) in the TPC grp
https://t.co/FetNERLBRf

[ogochukwu osita izu @docIzuog1995]

Vepdegestrant is the 1st PROTAC drug to treat a cancer (breast). There may be a PROTAC option for MM in the future - CBPD‑409.
@HenrychihangFu1 @Myeloma_Doc
@rajshekharucms
https://t.co/IV9gEDM4td

[ogochukwu osita izu @docIzuog1995]

@HatanMortada Well summarised 👍🏿

[ogochukwu osita izu @docIzuog1995]

@DextersRebirth @arealgoodfella @Rothmus Touché

[ogochukwu osita izu @docIzuog1995]

https://t.co/D1knsKlFHS
Tumor Genesis Syndrome is a rare oncologic condition characterized by severe electrolyte depletion, primarily marked by hypophosphatemia, caused by the excessive intake of phosphorus and other nutrients by rapidly multiplying cancer cells.

[ogochukwu osita izu @docIzuog1995]

@bloodcancer_uk 🙏🏿🙏🏿